Impact of CXCR4 and CXCR7 Knockout by CRISPR/Cas9 on the Function of Triple-negative Breast Cancer Cells

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Jun 14

PMID 31190884

Citations 29

Authors

Meng Yang

Chen Zeng

Peiting Li

Liyuan Qian

Boni Ding

Lihua Huang

Gang Li

Han Jiang

Ni Gong

Wei Wu

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is one of the most common malignancies threatening women's health. Triple-negative breast cancer (TNBC) is a special type of breast cancer with high invasion and metastasis. CXCL12 and its receptors CXCR4 and CXCR7 play a crucial role in the progress of breast cancer. The aim of this study was to investigate the effect of CXCR4 and CXCR7 on the function of TNBC.

Materials And Methods: We used the CRISPR/Cas9 technique to carry out a single knockout of the CXCR4 or CXCR7 gene and co-knockout of CXCR4 and CXCR7 genes in the TNBC cell line (MDA-MB-231). The single knockout and co-knockout cells were screened and verified by PCR sequencing and Western blot assay, the effect of single knockout and co-knockout on the proliferation of TNBC cells was examined using the Cell Counting Kit-8 and colony formation assays, the migration and invasion of TNBC cells were examined by the transwell and wound-healing assays, the changes in the cell cycle distribution after knockout were detected by flow cytometry, and the difference in the migration and invasion of single knockout and co-knockout induced by CXCL12 was observed by adding CXCL12 in the experimental group.

Results: The single knockout of the CXCR4 or CXCR7 gene significantly reduced the cell proliferation, growth, migration, and invasion and delayed the conversion of the G1/S cycle, while the co-knockout inhibited these biological abilities more significantly. In both the knockout and control groups, the migration and invasion of CXCL12-added cells were significantly stronger than those of the non-CXCL12-added cells, and CXCL12 induced lesser migration and invasion in the CXCR4 and CXCR7 co-knockout group than in the single knockout groups.

Conclusion: The knockout of the CXCR4 and CXCR7 genes affects the binding capacity and functions of CXCL12, inhibits the malignant progression of TNBC cells significantly, and may become a potential target for the treatment of TNBC.

Citing Articles

Connexin 43 hemichannels and related diseases.

Zhang Y, Acosta F, Jiang J Antib Ther. 2024; 7(4):361-369.

PMID: 39678258 PMC: 11646280. DOI: 10.1093/abt/tbae024.

From Biosensors to Robotics: Pioneering Advances in Breast Cancer Management.

Hasan M, Mughees M, Shaikh S, Choudhary F, Nizam A, Rizwan A Sensors (Basel). 2024; 24(18).

PMID: 39338894 PMC: 11435941. DOI: 10.3390/s24186149.

CRISPR/Cas9 systems: Delivery technologies and biomedical applications.

Du Y, Liu Y, Hu J, Peng X, Liu Z Asian J Pharm Sci. 2023; 18(6):100854.

PMID: 38089835 PMC: 10711398. DOI: 10.1016/j.ajps.2023.100854.

CRISPR-Based Gene Editing: a Modern Approach for Study and Treatment of Cancer.

Talukder P, Chanda S, Chaudhuri B, Choudhury S, Saha D, Dash S Appl Biochem Biotechnol. 2023; 196(7):4439-4456.

PMID: 37737443 DOI: 10.1007/s12010-023-04708-2.

CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics.

Tiwari P, Ko T, Dubey R, Chouhan M, Tsai L, Singh H Front Mol Biosci. 2023; 10:1214489.

PMID: 37469704 PMC: 10352522. DOI: 10.3389/fmolb.2023.1214489.

References

Muller A, Homey B, Soto H, Ge N, CATRON D, Buchanan M . Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410(6824):50-6. DOI: 10.1038/35065016. View

Liang Z, Yoon Y, Votaw J, Goodman M, Williams L, Shim H . Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005; 65(3):967-71. PMC: 3734941. View

Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel R, Jiang W . Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res. 2005; 7(4):R402-10. PMC: 1175055. DOI: 10.1186/bcr1022. View

Palm D, Lang K, Brandt B, Zaenker K, Entschladen F . In vitro and in vivo imaging of cell migration: two interdepending methods to unravel metastasis formation. Semin Cancer Biol. 2005; 15(5):396-404. DOI: 10.1016/j.semcancer.2005.06.008. View

Burns J, Summers B, Wang Y, Melikian A, Berahovich R, Miao Z . A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006; 203(9):2201-13. PMC: 2118398. DOI: 10.1084/jem.20052144. View

Rakha E, El-Sayed M, Green A, Lee A, Robertson J, Ellis I . Prognostic markers in triple-negative breast cancer. Cancer. 2006; 109(1):25-32. DOI: 10.1002/cncr.22381. View

Millikan R, Newman B, Tse C, Moorman P, Conway K, Dressler L . Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2007; 109(1):123-39. PMC: 2443103. DOI: 10.1007/s10549-007-9632-6. View

Miao Z, Luker K, Summers B, Berahovich R, Bhojani M, Rehemtulla A . CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A. 2007; 104(40):15735-40. PMC: 1994579. DOI: 10.1073/pnas.0610444104. View

Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta K . The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem. 2007; 283(7):4283-94. DOI: 10.1074/jbc.M707465200. View

10.

Hinton C, Avraham S, Avraham H . Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis. 2008; 27(2):97-105. DOI: 10.1007/s10585-008-9210-2. View

11.

Rubin J . Chemokine signaling in cancer: one hump or two?. Semin Cancer Biol. 2008; 19(2):116-22. PMC: 2694237. DOI: 10.1016/j.semcancer.2008.10.001. View

12.

Gassmann P, Haier J, Schluter K, Domikowsky B, Wendel C, Wiesner U . CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia. 2009; 11(7):651-61. PMC: 2697351. DOI: 10.1593/neo.09272. View

13.

Anders C, Carey L . Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009; 9 Suppl 2:S73-81. PMC: 2919761. DOI: 10.3816/CBC.2009.s.008. View

14.

Kollmar O, Rupertus K, Scheuer C, Nickels R, Haberl G, Tilton B . CXCR4 and CXCR7 regulate angiogenesis and CT26.WT tumor growth independent from SDF-1. Int J Cancer. 2009; 126(6):1302-15. DOI: 10.1002/ijc.24956. View

15.

Zheng K, Li H, Su X, Wang X, Tian T, Li F . Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2010; 29:31. PMC: 2859378. DOI: 10.1186/1756-9966-29-31. View

16.

Teicher B, Fricker S . CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010; 16(11):2927-31. DOI: 10.1158/1078-0432.CCR-09-2329. View

17.

Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J . CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010; 29(4):709-22. PMC: 3175097. DOI: 10.1007/s10555-010-9256-x. View

18.

Makarova K, Haft D, Barrangou R, Brouns S, Charpentier E, Horvath P . Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol. 2011; 9(6):467-77. PMC: 3380444. DOI: 10.1038/nrmicro2577. View

19.

Hernandez L, Magalhaes M, Coniglio S, Condeelis J, Segall J . Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res. 2011; 13(6):R128. PMC: 3326570. DOI: 10.1186/bcr3074. View

20.

Luker K, Lewin S, Mihalko L, Schmidt B, Winkler J, Coggins N . Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene. 2012; 31(45):4750-8. PMC: 3337948. DOI: 10.1038/onc.2011.633. View